97 related articles for article (PubMed ID: 30600949)
1. Th17 and IL-17 as Predictors of Hepatic Inflammation in Patients with Chronic Hepatitis C Virus Infection and Treated With Direct Antiviral Therapy.
Abou El-Khier NT; Elhammady D; Arafa MM; Shahin D; Eladl E; Abousamra NK; Sharaf-Eldeen O; Shaker G; Esmael ME
Egypt J Immunol; 2018 Jun; 25(2):61-74. PubMed ID: 30600949
[TBL] [Abstract][Full Text] [Related]
2. Immune response of Th17-associated cytokines by peripheral blood mononuclear cells from patients with chronic hepatitis C virus infection.
Cabral MS; Santos TPS; Santos PL; Schinoni MI; Oliveira IS; Pereira AB; Atta AM; Sousa-Atta MLB
Cytokine; 2018 Feb; 102():200-205. PubMed ID: 28969940
[TBL] [Abstract][Full Text] [Related]
3. Imbalance of regulatory T cells and T helper type 17 cells in patients with chronic hepatitis C.
Hao C; Zhou Y; He Y; Fan C; Sun L; Wei X; Wang L; Peng M; Wang P; Lian J; Jia Z
Immunology; 2014 Dec; 143(4):531-8. PubMed ID: 24903732
[TBL] [Abstract][Full Text] [Related]
4. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
[TBL] [Abstract][Full Text] [Related]
5. Intra-Hepatic Depletion of Mucosal-Associated Invariant T Cells in Hepatitis C Virus-Induced Liver Inflammation.
Bolte FJ; O'Keefe AC; Webb LM; Serti E; Rivera E; Liang TJ; Ghany M; Rehermann B
Gastroenterology; 2017 Nov; 153(5):1392-1403.e2. PubMed ID: 28780074
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.
Welzel TM; Nelson DR; Morelli G; Di Bisceglie A; Reddy RK; Kuo A; Lim JK; Darling J; Pockros P; Galati JS; Frazier LM; Alqahtani S; Sulkowski MS; Vainorius M; Akushevich L; Fried MW; Zeuzem S;
Gut; 2017 Oct; 66(10):1844-1852. PubMed ID: 27418632
[TBL] [Abstract][Full Text] [Related]
8. Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.
Swallow E; Song J; Yuan Y; Kalsekar A; Kelley C; Peeples M; Mu F; Ackerman P; Signorovitch J
Clin Ther; 2016 Feb; 38(2):404-12. PubMed ID: 26839044
[TBL] [Abstract][Full Text] [Related]
9. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study.
Iqbal S; Yousuf MH; Yousaf MI
World J Gastroenterol; 2017 Nov; 23(44):7899-7905. PubMed ID: 29209131
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.
Taneja S; Duseja A; De A; Kumar V; Ramachandran R; Sharma A; Dhiman RK; Gupta KL; Chawla Y
Nephrology (Carlton); 2018 Sep; 23(9):876-882. PubMed ID: 28703905
[TBL] [Abstract][Full Text] [Related]
11. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2).
Lawitz E; Matusow G; DeJesus E; Yoshida EM; Felizarta F; Ghalib R; Godofsky E; Herring RW; Poleynard G; Sheikh A; Tobias H; Kugelmas M; Kalmeijer R; Peeters M; Lenz O; Fevery B; De La Rosa G; Scott J; Sinha R; Witek J
Hepatology; 2016 Aug; 64(2):360-9. PubMed ID: 26704148
[TBL] [Abstract][Full Text] [Related]
12. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03).
Wehmeyer MH; Ingiliz P; Christensen S; Hueppe D; Lutz T; Simon KG; Schewe K; Boesecke C; Baumgarten A; Busch H; Rockstroh J; Schmutz G; Kimhofer T; Berger F; Mauss S; Schulze Zur Wiesch J
J Med Virol; 2018 Feb; 90(2):304-312. PubMed ID: 28710853
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.
Terrault NA; Zeuzem S; Di Bisceglie AM; Lim JK; Pockros PJ; Frazier LM; Kuo A; Lok AS; Shiffman ML; Ben Ari Z; Akushevich L; Vainorius M; Sulkowski MS; Fried MW; Nelson DR;
Gastroenterology; 2016 Dec; 151(6):1131-1140.e5. PubMed ID: 27565882
[TBL] [Abstract][Full Text] [Related]
14. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
[TBL] [Abstract][Full Text] [Related]
15. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
Charlton M; Everson GT; Flamm SL; Kumar P; Landis C; Brown RS; Fried MW; Terrault NA; O'Leary JG; Vargas HE; Kuo A; Schiff E; Sulkowski MS; Gilroy R; Watt KD; Brown K; Kwo P; Pungpapong S; Korenblat KM; Muir AJ; Teperman L; Fontana RJ; Denning J; Arterburn S; Dvory-Sobol H; Brandt-Sarif T; Pang PS; McHutchison JG; Reddy KR; Afdhal N;
Gastroenterology; 2015 Sep; 149(3):649-59. PubMed ID: 25985734
[TBL] [Abstract][Full Text] [Related]
16. Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.
Butt AA; Yan P; Shaikh OS; Chung RT; Sherman KE;
Liver Int; 2016 Sep; 36(9):1275-83. PubMed ID: 26928927
[TBL] [Abstract][Full Text] [Related]
17. Sofosbuvir plus ribavirin for the treatment of hepatitis C virus genotype 2 in Korea: What's the optimal dosage of ribavirin in real-world setting?
Yoon JH; Jun CH; Seo JH; Cho HA; Cho SB; Choi SK; Cho JY; Kim MW; Lim SW
J Dig Dis; 2019 Jan; 20(1):31-37. PubMed ID: 30548199
[TBL] [Abstract][Full Text] [Related]
18. Involvement of the Interleukin-23/Interleukin-17 Axis in Chronic Hepatitis C Virus Infection and Its Treatment Responses.
Meng P; Zhao S; Niu X; Fu N; Su S; Wang R; Zhang Y; Qiao L; Nan Y
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27428948
[TBL] [Abstract][Full Text] [Related]
19. Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea.
Cho Y; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
Clin Mol Hepatol; 2015 Dec; 21(4):358-64. PubMed ID: 26770924
[TBL] [Abstract][Full Text] [Related]
20. Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for Recurrent Infection After Liver Transplantation.
Elmasry S; Wadhwa S; Bang BR; Cook L; Chopra S; Kanel G; Kim B; Harper T; Feng Z; Jerome KR; Kahn JA; Saito T
Gastroenterology; 2017 Feb; 152(3):550-553.e8. PubMed ID: 27838287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
